News Release

Efficacy, tolerability of gefapixant for treatment of refractory or unexplained chronic cough


Peer-Reviewed Publication

JAMA Network

About The Study: In this dose-response meta-analysis that included nine randomized clinical trials and 2,980 patients, compared with placebo, gefapixant (45 mg orally twice daily) led to modest improvements in cough frequency, cough severity, and cough-specific quality of life but increased taste-related adverse events.

Authors: Imran Satia, M.D., Ph.D., of McMaster University in Hamilton, Ontario, Canada, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: This study is being released to coincide with presentation at the European Respiratory Society International Congress 2023.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.